Centocor
Executive Summary
J&J subsidiary will pay up to $50 mil. for 3-Dimensional Pharmaceuticals' orally active direct thrombin inhibitor program. Centocor will make a cash payment of $6 mil. up front, with up to an additional $44 mil. in milestone payments for the first compound marketed. 3DP will receive additional milestone payments on future products and royalties on the sale of any product marketed under the agreement. 3DP retains an option to co-develop and co-promote the deep vein thrombosis indication. The firm's leading anticoagulant compound, 3DP-4815, is in Phase I trials. 3DP's agreement with Wyeth-Ayerst for the same thrombin inhibitor technology was terminated in June 1999
You may also be interested in...
J&J Adds New Dimension To Drug Discovery Efforts With 3DP Acquisition
Johnson & Johnson's purchase of 3-Dimensional Pharmaceuticals has more of a research focus than its other recent drug acquisitions
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011